Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Netscientific PLC RNS Release

Vortex Biosciences CSO Finalist for SLAS Award

RNS Number : 3927W
NetScientific PLC
09 February 2017
 

 

 

NetScientific plc

("NetScientific" or the "Company" or the "Group")

 

Vortex Biosciences' Chief Scientific Officer, Elodie Sollier, Selected as Finalist for 2017 SLAS Innovation Award

London, UK - 9 February 2017 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, is delighted to report that the Chief Scientific Officer of its portfolio company, Vortex Biosciences, Elodie Sollier, has been selected as a finalist for a 2017 SLAS Innovation Award.

Elodie, who is one of nine finalists, gave a presentation to the judges on Monday 6 February: "Vortex Technology for fast and label-free isolation of circulating tumour cells from blood samples" where she discussed a breakthrough by Vortex in the isolation of circulating tumour cells from blood samples.  Her presentation will be considered by the judges in determining the winner of the award.

The annual SLAS Innovation Award recognizes extraordinary achievement in innovative life sciences discovery and technology. All those selected to deliver podium presentations at the annual SLAS conference are eligible to be considered for this award, which comes with a $10,000 prize.

Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific, said: "The SLAS Innovation Award is a prestigious award with rigorous judging criteria. This is a recognition for Vortex on the design of the VTX-1 Liquid Biopsy System, with regards to its novel science and potential impact on laboratory automation and screening.

 

"I am delighted to see Vortex's unique VTX-1 technology get the profile it deserves, which we believe will help the company as it moves into commercialisation phase. We wish Elodie the best of luck with the award."

 

The full text of the announcement is below:

 

 

Vortex Biosciences Selected as Finalist for 2017 SLAS Innovation Award

 

Elodie Sollier CSO of Vortex Biosciences is Presenting at SLAS as 1 of 9 Finalists for the Innovation Award

MENLO PARK, CA, February 6 - Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced that Chief Scientific Officer (CSO) Elodie Sollier has been selected as 1 of 9 finalists for the 2017 SLAS Innovation Award. Elodie is a candidate for the award based on her presentation titled "Vortex Technology for fast and label-free isolation of circulating tumor cells from blood samples" which will be presented at SLAS on Monday February 6th at 4:30 pm. As 1 of the 9 finalists, a panel of judges will evaluate her presentation and compare it with the other finalists to determine the winner of the 2017 award.

 

The annual SLAS Innovation Award recognizes extraordinary achievement in innovative life sciences discovery and technology. All those selected to deliver podium presentations at the annual SLAS conference are eligible to be considered for this award.  After receiving nominations from 83 SLAS 2017 podium presenters, the SLAS Innovation Award panel of judges invited 21 presenters to submit extended abstracts for further consideration. Of these 21 extended abstracts, 9 were identified as finalists. The complete judging criteria can be seen on the Innovation Award page of the SLAS 2017 website.

"I am honored to be one of the finalists for something as prestigious as the 2017 SLAS Innovation Award," said Elodie Sollier, Chief Scientific Officer of Vortex Biosciences. "This is further validation of the breakthrough technology the Vortex VTX-1 Liquid Biopsy System represents and the impact this will have on cancer patients."

CTCs are relatively scarce, with concentrations as low as 1-10 CTCs/mL of whole blood, against a background of millions of white blood cells and billions of red blood cells. Existing CTC isolation technologies have been limited by complex sample processing, poor scalability, low sample purity, reliance on cell surface proteins for isolation, and dilute output volumes that require additional cell concentration steps.

 

The fully automated, easy to use VTX-1 Liquid Biopsy System from Vortex represents the next step in CTC isolation. Inside the VTX-1 chip, unlabeled CTCs in whole blood are selectively trapped in microscale vortices while smaller red and white blood cells pass through. Afterwards, CTCs can be collected into a variety of containers for downstream analysis. With a cancer cell recovery of 65-75% and best in class CTC purity. The CTCs collected are unbiased by their molecular characteristics. These cells are intact, viable, and ready for downstream analysis. The VTX-1 offers the best CTC samples available today.

 

 

 

For more information, please contact:

 

  NetScientific

  François R. Martelet, M.D., CEO

  Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

 

Stifel Nicolaus Europe Limited

Jonathan Senior

David Arch

Ben Maddison

 

Consilium Strategic Communications

  Mary-Jane Elliott / Chris Gardner /

  Jessica Hodgson / Chris Welsh /

  Laura Thornton   

 Tel +44 207 710 7624  

 

 

Tel: +44 (0)20 3709 5700

[email protected]

 

 

About NetScientific Plc

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.

For more information, please visit the website at www.netscientific.net

About Vortex Biosciences

Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient's treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit www.vortexbiosciences.com.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALFFLIFAITIID



Netscientific PLC Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use